Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
103 participants
INTERVENTIONAL
2004-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue Sarcomas
NCT00087997
STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
NCT00088088
Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
NCT01014351
A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy
NCT00447421
Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
NCT02038647
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
STA-4783
Paclitaxel
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ECOG performance status of greater than or equal to 2
* Measurable disease per RECIST criteria
* Received no more than 1 regimen of prior chemotherapy (unlimited immunotherapy regimens are allowed)
* At least 4 weeks have passed since last chemotherapy or immunotherapy
* At least 2 weeks have passed since last radiotherapy.
* Life expectancy of greater than 12 weeks
* Clinical lab values within protocol parameters
Exclusion Criteria
* Female patients of childbearing potential not using or not willing to use effective contraception
* Presence of a second malignancy other than nonmelanoma skin cancer
* Presence of a clinically significant and uncontrolled infection
* Presence of clinically significant arrythmias
* Presence of serious concurrent illness or other conditions that do not permit adequate follow-up and compliance with protocol
* History of severe hypersensitivity reactions to taxanes
* Use of any investigational agents within 4 weeks prior to the first dose of study drug
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Synta Pharmaceuticals Corp.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Genesis Cancer Center
Hot Springs, Arkansas, United States
Univ Of Arkansas/Arkansas Research Center
Little Rock, Arkansas, United States
Scripps Cancer Center
San Diego, California, United States
Northern California Melanoma Center
San Francisco, California, United States
Cancer Institute Medical Group, Inc
Santa Monica, California, United States
Anschutz Cancer Pavillion - Univ Of Colorado
Aurora, Colorado, United States
Hematology Oncology P.C.
Stamford, Connecticut, United States
Medical Oncology and Hematology, P.C.
Waterbury, Connecticut, United States
Emory University - Winship Cancer Institute
Atlanta, Georgia, United States
Research Institute Hawaii Pacific Health
Honolulu, Hawaii, United States
Joliet Oncology-Hematology Associates, Ltd.
Joliet, Illinois, United States
Oncology Specialists
Park Ridge, Illinois, United States
Cancer Care Center Of Southern Indiana
Bloomington, Indiana, United States
Center For Cancer Care At Goshen Health
Goshen, Indiana, United States
Indiana Oncology Hematology Consultants
Iindianapolis, Indiana, United States
Cancer Care Center
New Albany, Indiana, United States
James Graham Brown Cancer Center - University Of Louisville
Louisville, Kentucky, United States
Maine Center for Cancer Medicine & Blood Disorders
Scarborough, Maine, United States
Hubert H. Humphrey Cancer Center
Robbinsdale, Minnesota, United States
Ellis Fischels Cancer Center - Univ Of Missouri
Columbia, Missouri, United States
Mountainside Hospital, Suburban Surgical Associates
St Louis, Missouri, United States
Piedmont Oncology Specialists
Charlotte, North Carolina, United States
Odyssey Research and St. Alexius Medical Center
Bismarck, North Dakota, United States
Providence Cancer Center
Portland, Oregon, United States
Danville Hematology & Oncology, Inc.
Danville, Virginia, United States
Office of James Stark, MD
Portsmouth, Virginia, United States
Virginia Cancer Institute
Richmond, Virginia, United States
University of Wisconsin Medical School
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
4783-03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.